1. Search Result
Search Result
Results for "

profile

" in MedChemExpress (MCE) Product Catalog:

187

Inhibitors & Agonists

4

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

6

Peptides

1

Inhibitory Antibodies

16

Natural
Products

1

Isotope-Labeled Compounds

7

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-133018

    HCV Infection
    HCV-IN-7 is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC50s of 3-47 pM. HCV-IN-7 shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 has anti-viral activity .
    HCV-IN-7
  • HY-133018A

    HCV Cancer
    HCV-IN-7 hydrochloride is an orally active and potent pan-genotypic HCV NS5A inhibitor with IC50s of 3-47 pM. HCV-IN-7 hydrochloride shows a superior pan-genotypic profile and a good pharmacokinetic profile coupled with a favorable liver uptake. HCV-IN-7 hydrochloride has anti-viral activity .
    HCV-IN-7 hydrochloride
  • HY-155652

    BCRP Cancer
    ABCG2-IN-1 (compound K2), a Ko143 analog, is an orally active ABCG2 inhibitor with an IC50 of 0.13 μM. ABCG2-IN-1 has favorable oral pharmacokinetic profiles in mice .
    ABCG2-IN-1
  • HY-115494

    Neladenoson bialanate hydrochloride; BAY-1067197 hydrochloride

    Adenosine Receptor Cardiovascular Disease
    Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) hydrochloride is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate hydrochloride has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases .
    Neladenoson dalanate hydrochloride
  • HY-123353

    Neladenoson bialanate; BAY-1067197

    Adenosine Receptor Cardiovascular Disease
    Neladenoson dalanate (Neladenoson bialanate; BAY-1067197) is a orally active agonist precursor of partial Adenosine A1 Receptor. Neladenoson dalanate has a good pharmacokinetic and safety profile, can be used for the chronic heart diseases .
    Neladenoson dalanate
  • HY-P9989

    REGN5458

    CD3 TNF Receptor Cancer
    Linvoseltamab is a bispecific antibody targeting to both BCMA (TNFRSF17) and CD3 epsilon. Linvoseltamab shows safety profile and encouraging efficacy in relapsed/refractory multiple myeloma (RRMM) models .
    Linvoseltamab
  • HY-146380

    Histone Demethylase Cancer
    S1427 is a tranylcypromine-derived LSD1 inhibitor with the IC50 of 390 nM and Ki of 80 nM. S1427 exhibits desirable hERG channel inhibition and microsomal stability profiles. Inhibition of LSD1 partially reduces the proliferation of cancer cells .
    S1427
  • HY-10096

    GSK-3 Neurological Disease
    TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent GSK-3β inhibitor with the IC50 of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease .
    TCS2002
  • HY-103112

    5-HT Receptor Neurological Disease
    SB 243213 hydrochloride is an orally active, selective and high-affinity 5-HT2C receptor antagonist with a pKi of 9.37 and a pKb of 9.8 for human 5-HT2C receptor. SB 243213 hydrochloride shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 hydrochloride has improved anxiolytic profile and has the potential for schizophrenia and motor disorders .
    SB 243213 hydrochloride
  • HY-103112A

    5-HT Receptor Neurological Disease
    SB 243213 dihydrochloride is an orally active, selective and high-affinity 5-HT2C receptor antagonist with a pKi of 9.37 and a pKb of 9.8 for human 5-HT2C receptor. SB 243213 dihydrochloride shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 dihydrochloride has improved anxiolytic profile and has the potential for schizophrenia and motor disorders .
    SB 243213 dihydrochloride
  • HY-103112B

    5-HT Receptor Neurological Disease
    SB 243213 is an orally active, selective and high-affinity 5-HT2C receptor antagonist with a pKi of 9.37 and a pKb of 9.8 for human 5-HT2C receptor. SB 243213 shows greater than a 100-fold selectivity over a wide range of neurotransmitter receptors, enzymes and ion channels. SB 243213 has improved anxiolytic profile and has the potential for schizophrenia and motor disorders .
    SB 243213
  • HY-148254

    Deubiquitinase Cancer
    8RK64 is a covalent UCHL1 inhibitor (IC50: 0.32 μM) . 8RK64 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.
    8RK64
  • HY-115721

    Parasite Infection
    Antimalarial agent 2 is a novel orally efficacious antimalarials that suggests a fast in vitro killing profile.
    Antimalarial agent 2
  • HY-132867

    Pim Cancer
    MNK/PIM-IN-1 represents an innovative dual MNK/PIM inhibitor with a good pharmacokinetic profile.
    MNK/PIM-IN-1
  • HY-N2842

    Others Inflammation/Immunology
    α-Amyrin acetate, a natural triterpenoid, has anti-inflammatory activity, antispasmodic profile and the relaxant effect .
    α-Amyrin acetate
  • HY-W005178

    Endogenous Metabolite Others
    Octadecanedioic acid, an endogenous metabolite, is a long-chain dicarboxylic acid that has been found in serum free fatty acid profile in Reye syndrome .
    Octadecanedioic acid
  • HY-13219

    COX Lipoxygenase Inflammation/Immunology
    Tepoxalin is a dual inhibitor of COX and 5-lipoxygenase (5-LO) with potent anti-inflammatory activity and a favorable gastrointestinal profile .
    Tepoxalin
  • HY-13829

    HIV Infection
    BMS-585248 is a potent, third-generation HIV-1 attachment inhibitor with a promising initial in vitro and in vivo pharmacokinetic profile .
    BMS-585248
  • HY-108711

    Free Fatty Acid Receptor Metabolic Disease
    GPR120 Agonist 1 is a potent and selective GPR120 agonist, and possesses promising antidiabetic effect and good safety profile to be a development candidate .
    GPR120 Agonist 1
  • HY-108609

    Phospholipase Inflammation/Immunology
    YM-26734 is a competitive inhibitor of secretory phospholipase A 2 (PLA 2) that exhibits a broad inhibitory profile to several PLA2s .
    YM-26734
  • HY-122620

    Thrombopoietin Receptor Inflammation/Immunology Cancer
    Hetrombopag is a potent thrombopoietin receptor agonist. Hetrombopag is efficacious and well tolerated with a manageable safety profile. Hetrombopag has the potential for the research of immune thrombocytopenia .
    Hetrombopag
  • HY-P4062

    BIL

    Insulin Receptor Metabolic Disease
    Insulin peglispro (BIL) is a basal insulin with a flat, prolonged activity profile. Insulin peglispro can exhibit better glycaemic control compared to conventional insulins .
    Insulin peglispro
  • HY-111199

    FAAH Neurological Disease
    JP83 is an irreversible fatty acyl amide hydrolase (FAAH) inhibitor with an IC50 of 1.6 nM in competitive activity-based protein profiling (ABPP) experiments .
    JP83
  • HY-145285

    Apelin Receptor (APJ) Cardiovascular Disease
    APJ receptor agonist 5 (compound 3) is a potent and orally active agonist of apelin receptor (APJ) with an EC50 of 0.4 nM. APJ receptor agonist 5 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 5 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 5 leads to improved cardiac function and can be used for researching the HF disease .
    APJ receptor agonist 5
  • HY-N1798

    Quercetin 3,7-dimethyl ether, isolated from Croton schiedeanus Schlecht, has a NO/cGMP pathway-related profile, with increased vasorelaxant activity .
    Quercetin 3,7-dimethyl ether
  • HY-145284

    Apelin Receptor (APJ) Cardiovascular Disease
    APJ receptor agonist 4 is a potent and orally active agonist of apelin receptor (APJ) with EC50 and Ki of 0.06 nM and 0.07 nM respectively. APJ receptor agonist 4 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 4 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 4 leads to improved cardiac function and can be used for researching the HF disease .
    APJ receptor agonist 4
  • HY-109555

    HMR 1964

    Insulin Receptor Metabolic Disease
    Insulin glulisine (HMR 1964) is a rapid-acting insulin analogue, it mimics the pharmacokinetic and pharmacodynamic profiles of physiological human insulin. Insulin glulisine can be used for the research of diabetes .
    Insulin glulisine
  • HY-114301

    Sodium Channel Neurological Disease
    PF-06305591 is a potent and highly selective voltage gated sodium channel NaV1.8 blocker, with an IC50 of 15 nM. An excellent preclinical in vitro ADME and safety profile .
    PF-06305591
  • HY-16421

    (-)-DRF 2725; NNC 61-0029

    PPAR Metabolic Disease
    Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.
    Ragaglitazar
  • HY-144291

    Dopamine Receptor Neurological Disease
    LY3154885 is an orally active dopamine D1 receptor positive allosteric modulator (PAM). LY3154885 has an improved agent-agent interactions (DDI) risk profile .
    LY3154885
  • HY-135737
    Dicaprylyl carbonate
    1 Publications Verification

    Others Others
    Dicaprylyl carbonate, a solid, plant-derived fat, is a dry emollient. Dicaprylyl carbonate has excellent dermatological compatibility and a comprehensive performance profile, such as solubilizing and dispersing ability for sun-care filters .
    Dicaprylyl carbonate
  • HY-114301A

    Sodium Channel Neurological Disease
    PF-06305591 dihydrate is a potent and highly selective voltage gated sodium channel NaV1.8 blocker, with an IC50 of 15 nM. An excellent preclinical in vitro ADME and safety profile .
    PF-06305591 dihydrate
  • HY-119926

    Hydroxylupanine

    Others Cardiovascular Disease Neurological Disease
    13-Hydroxylupanine (Hydroxylupanine) is the typical alkaloid profile of sweet lupins.13-Hydroxylupanine blocks ganglionic transmission, decreases cardiac contractility and contracts uterine smooth muscle .
    13-Hydroxylupanine
  • HY-119926A

    Hydroxylupanine hydrochloride

    Others Cardiovascular Disease Neurological Disease
    13-Hydroxylupanine Hydroxylupanine is the typical alkaloid profile of sweet lupins. 13-Hydroxylupanine Hydroxylupanine blocks ganglionic transmission, decreases cardiac contractility and contracts uterine smooth muscle .
    13-Hydroxylupanine hydrochloride
  • HY-117690

    PROTACs Epigenetic Reader Domain Cancer
    dBRD9,a PROTAC, can selective degrades BRD9. dBRD9 improves the bromine domain binding profile and reduces the binding activity of the whole BET family .
    dBRD9
  • HY-B2209B
    Hydroxocobalamin acetate
    1 Publications Verification

    Vitamin B12a acetate

    Endogenous Metabolite Metabolic Disease
    Hydroxocobalamin acetate is an injectable naturally occurring form of vitamin B12 with a favorable adverse effect profile, used as a dietary supplement in the research of vitamin B12 deficiency including pernicious anemia .
    Hydroxocobalamin acetate
  • HY-12883A

    Sodium Channel Neurological Disease
    PF-05198007 is a potent, orally active and selective arylsulfonamide Nav1.7 inhibitor. PF-05198007 is a compound with a similar pharmacodynamic profile to PF-05089771 .
    PF-05198007
  • HY-145362

    LPL Receptor Others
    S1P1 agonist 4 has a better profile in both potency (EC50 < 0.05 mg/kg) and predicted human half-life (t1/2 ∼ 5 days).
    S1P1 agonist 4
  • HY-B2209C

    Vitamin B12a hydrochloride

    Endogenous Metabolite Metabolic Disease
    Hydroxocobalamin hydrochloride is an injectable naturally occurring form of vitamin B12 with a favorable adverse effect profile, used as a dietary supplement in the research of vitamin B12 deficiency including pernicious anemia .
    Hydroxocobalamin hydrochloride
  • HY-148739

    PROTACs Epigenetic Reader Domain Cancer
    dBRD 9-A is a PROTAC which can selective degrade BRD9. dBRD 9-A improves the bromine domain binding profile and reduces the binding activity of the whole BET family .
    dBRD 9-A
  • HY-120802

    AZD-8871; LAS191351

    mAChR Adrenergic Receptor Inflammation/Immunology
    Navafenterol (AZD-8871) is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC50 is 9.5 for human M3 receptor, and the pEC50 is 9.5 for β2-adrenoceptor. Navafenterol can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile .
    Navafenterol
  • HY-14305A
    BMS-582949 hydrochloride
    1 Publications Verification

    p38 MAPK Autophagy Inflammation/Immunology
    BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC50 of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease .
    BMS-582949 hydrochloride
  • HY-12352A

    STAT Apoptosis Cancer
    HJC0416 hydrochloride is a potent and orally active STAT3 inhibitor with an enhanced anticancer profile than Stattic (HY-13818). HJC0416 hydrochloride is a promising anti-cancer agent for breast cancer study .
    HJC0416 hydrochloride
  • HY-116524

    5-HT Receptor Neurological Disease
    PF-04781340 is a potent and selective 5-HT2C receptor agonist. PF-04781340 is orally available and have central nervous system penetrant profile .
    PF-04781340
  • HY-D1082

    Fluorescent Dye Others
    5-DTAF is a isomeric fluorescein derivative that directly react with polysaccharides and other alcohols in aqueous solution at pH > 9. The maximum of the 5-DTAF emission profile is at a wavelength of 518 nm after excitation at 488 nm .
    5-DTAF
  • HY-157132

    FAAH Neurological Disease
    FAAH-IN-8 (compound 11) is a competitive inhibitor of FAAH with an IC50 value of 6.7 nM and a Ki value of 5 nM. FAAH-IN-8 has high blood-brain permeability and a significant antioxidant profile with no neurotoxicity .
    FAAH-IN-8
  • HY-110131

    nAChR Neurological Disease
    A 85380 hydrochloride is a novel, high affinity neuronal nicotinic acetylcholine receptor (nAChR) agonist. A 85380 hydrochloride exhibits selectivity for the α4β2 nAChR subtypes. A 85380 hydrochloride has a broad-spectrum analgesic profile .
    A 85380 hydrochloride
  • HY-161178

    Bacterial Infection
    LK-60 is a potent DprE1 inhibitor. LK-60 effectively inhibits the proliferation of Mycobacterium tuberculosis. LK-60 has good safety profiles to gut microbiota and human cells .
    LK-60
  • HY-120802A

    AZD-8871 saccharinate; LAS191351 saccharinate

    mAChR Adrenergic Receptor Infection Inflammation/Immunology
    Navafenterol (AZD-8871) saccharinate is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC50 is 9.5 for human M3 receptor, and the pEC50 is 9.5 for β2-adrenoceptor. Navafenterol saccharinate can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile .
    Navafenterol saccharinate
  • HY-119402

    BCL6-IN-8c

    Bcl-2 Family Cancer
    TP-021 (BCL6-IN-8c) is a potent and orally active B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor with an IC50 of 0.10 µM in cell-free enzyme-linked immunosorbent assay .
    TP-021

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: